# A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject

> **NCT05147259** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Diabetes in Adults

## Interventions

- **DRUG:** HR011408 injection

## Key facts

- **NCT ID:** NCT05147259
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-29
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-02-16
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05147259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05147259, "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05147259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*